🧾 What This Document Is

This is an 8-K filing with a key Exhibit 99.1 attached. Think of an 8-K as a "current report" companies use to announce major, time-sensitive news to investors. This specific announcement is a formal notification from the Nasdaq stock exchange.

👉 In simple terms: InMed got a warning letter from Nasdaq because its stock price has been too low for too long. It's a serious heads-up, but not an immediate crisis.

🏢 What The Company Does

InMed Pharmaceuticals is a biotech company. They research and develop new small-molecule drugs.

👉 In simple terms: They are like drug detectives, creating new medicines that target specific receptors (called CB1 and CB2) in the body. Their research focuses on diseases like Alzheimer's, eye conditions, and skin disorders.

⚠️ The Nasdaq Warning: What Happened

Nasdaq has strict rules for companies listed on its exchange. One key rule is that a stock's closing price must stay above $1.00 per share.

The problem: InMed's stock price closed below $1.00 for 30 consecutive trading days, from February 11, 2026, to March 26, 2026. Because of this, Nasdaq sent a formal notice of non-compliance on March 27, 2026.

👉 Why it matters: This is a yellow flag. It signals to the market that the company is at risk of losing its prestigious Nasdaq listing, which could make it harder to raise money and could lead to less investor interest.

🔍 The Cure Period & The Rules

Receiving the notice does not mean InMed's stock will be delisted immediately. The company has a grace period to fix the problem.

• The Main Clock: InMed has 180 calendar days from receiving the notice (so until approximately late September 2026) to get its stock price back up.
• How to Regain Compliance: The stock price must meet or exceed $1.00 per share for at least 10 consecutive business days during that 180-day window.
• Possible Extension: If InMed doesn't fix it in 180 days, they might qualify for a second 180-day grace period. To get it, they would need to meet all other listing requirements and formally notify Nasdaq of their plan to fix the price, potentially by doing a reverse stock split.

👉 Key takeaway: The company has time, but a plan of action is needed. A reverse stock split (which reduces the number of shares and raises the price per share) is a common, though not ideal, tool used in these situations.

🚀 What Happens If They Don't Fix It?

If InMed fails to regain compliance within the allowed time frames, Nasdaq will send a delisting notice.

At that point, InMed could appeal the decision to a Nasdaq Hearings Panel. However, their stock would be automatically suspended from trading on Nasdaq while the appeal is being decided. There's no guarantee an appeal would work.

👉 Why it matters: Being delisted from Nasdaq would force the stock to trade on smaller, less regulated markets (like the OTC markets), which typically leads to lower trading volume, less investor visibility, and a negative perception.

💡 What's Next & Company's Response

InMed stated it will monitor its closing share price and explore available options to regain compliance. This language is standard; companies in this position often consider strategies like reverse splits, securing new financing to boost investor sentiment, or sharing positive business developments to drive the stock price up.

The company's stock will continue to trade under the symbol "INM" for now.

⚖️ Big Picture: Strengths & Risks

• 👍 Strength: The listing is safe for now. The company has a clear, defined timeline (at least 180 days) to address the issue. Their underlying business of researching Alzheimer's and other disease treatments continues.
• ⚠️ Major Risk: This is a direct threat to the company's market standing and liquidity. A low stock price can hinder their ability to raise capital through stock offerings, which biotech companies heavily rely on to fund research. The potential for a reverse split can also concern investors as it often signals underlying weakness.

🧠 The Analogy

This is like a student getting a formal warning that their GPA has fallen below the minimum required to stay in a prestigious program. They aren't expelled yet—they're put on academic probation. They have one semester (the grace period) to bring their grades up. If they fail, they might get another chance (the extension), but only if they show a serious plan (like taking extra classes). If they still fail, they get kicked out of the program and have to transfer to a less renowned school.

📇 Key Contacts & People

• Company Contact: InMed Pharmaceuticals Inc.
• Address: 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8
• Phone: +1.604.669.7207
• Email: [email protected]
• Website: www.inmedpharma.com
• Investor Contact: Colin Clancy, Vice President, Investor Relations and Corporate Communications
• Investor Phone: +1.604.416.0999
• Investor Email: [email protected]

🧩 Final Takeaway

InMed Pharmaceuticals has received a serious but not fatal warning from Nasdaq about its low stock price. The clock is ticking, and the company now has about six months to execute a plan—likely involving a reverse stock split—to keep its listing on the major exchange. The stability of its stock and its ability to fund future drug research are now directly tied to solving this problem.